## Helen V Rees

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7871397/publications.pdf

Version: 2024-02-01

194 papers 11,036 citations

54 h-index 97 g-index

200 all docs

200 docs citations

200 times ranked 10302 citing authors

#	Article	IF	CITATIONS
1	Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before–after design. BMJ Open, 2022, 12, e059968.	1.9	5
2	Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition – A Nested Case-Control Study in HIV-1 Serodiscordant Couples. Frontiers in Immunology, 2022, 13, 813412.	4.8	1
3	Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply. Lancet, The, 2022, 399, 1225.	13.7	1
4	High HIV incidence among young women in South Africa: Data from a large prospective study. PLoS ONE, 2022, 17, e0269317.	2.5	4
5	Trajectories of fertility intentions among women living with HIV in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 180-186.	1.2	1
6	Placebo-Controlled Trials of Covid-19 Vaccines â€" Why We Still Need Them. New England Journal of Medicine, 2021, 384, e2.	27.0	66
7	Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sexually Transmitted Infections, 2021, 97, 249-255.	1.9	17
8	Complete pathological response after ceritinib for anaplastic lymphoma kinaseâ€rearranged epithelioid peritoneal mesothelioma. ANZ Journal of Surgery, 2021, 91, 475-476.	0.7	0
9	SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 2021, 385, 179-186.	27.0	322
10	Genetic Analysis of a Cohort of 275 Patients with Hyper-IgE Syndromes and/or Chronic Mucocutaneous Candidiasis. Journal of Clinical Immunology, 2021, 41, 1804-1838.	3.8	12
11	Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study. Lancet HIV,the, 2021, 8, e495-e501.	4.7	16
12	Considerations in boosting COVID-19 vaccine immune responses. Lancet, The, 2021, 398, 1377-1380.	13.7	267
13	HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 376-383.	2.1	1
14	Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. Clinical Infectious Diseases, 2021, , .	5.8	2
15	Fertility Intentions and Clinical Care Attendance Among Women Living with HIV in South Africa. AIDS and Behavior, 2020, 24, 1585-1591.	2.7	4
16	HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use. Lancet HIV,the, 2020, 7, e141-e148.	4.7	2
17	Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution. European Journal of Cancer, 2020, 140, 63-70.	2.8	12
18	Age-Specific Risk Scores Do Not Improve HIV-1 Prediction Among Women in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 156-164.	2.1	13

#	Article	IF	Citations
19	Integrating oral PrEP delivery among African women in a large HIV endpointâ€driven clinical trial. Journal of the International AIDS Society, 2020, 23, e25491.	3.0	18
20	Prioritisation of the human papillomavirus vaccine in a time of constrained supply. The Lancet Child and Adolescent Health, 2020, 4, 349-351.	5.6	6
21	Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression. AIDS Research and Human Retroviruses, 2020, 36, 632-640.	1.1	1
22	COVID-19 in Africa: care and protection for frontline healthcare workers. Globalization and Health, 2020, 16, 46.	4.9	272
23	ECHO: context and limitations – Authors' reply. Lancet, The, 2020, 395, e27.	13.7	2
24	Contraceptive implant uptake in Kenya versus South Africa: Lessons for new implantable technologies. Contraception, 2020, 101, 220-225.	1.5	1
25	<i>STRN-ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment. JCO Precision Oncology, 2019, 3, 1-6.	3.0	21
26	Climate change and control of diarrhoeal diseases in South Africa: Priorities for action. South African Medical Journal, 2019, 109, 359.	0.6	5
27	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. Journal of the International AIDS Society, 2019, 22, e25372.	3.0	15
28	Climate change and adolescents in South Africa: The role of youth activism and the health sector in safeguarding adolescents' health and education. South African Medical Journal, 2019, 109, 615.	0.6	7
29	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet, The, 2019, 394, 303-313.	13.7	230
30	Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission. Journal of Virology, 2019, 93, .	3.4	4
31	"l am still negative― Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. PLoS ONE, 2019, 14, e0212271.	2.5	26
32	Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine, 2019, 37, 2258-2267.	3.8	13
33	The impact of decentralising colposcopy services from tertiary-level to primary-level care in inner-city Johannesburg, South Africa: a before and after study. BMJ Open, 2019, 9, e024726.	1.9	3
34	Vaccinology in sub-Saharan Africa. BMJ Global Health, 2019, 4, e001363.	4.7	8
35	Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. Aids, 2019, 33, 185-197.	2.2	11
36	Integrating Cervical Cancer Screening Into Safer Conception Services to Improve Women's Health Outcomes: A Pilot Study at a Primary Care Clinic in South Africa. Sexually Transmitted Diseases, 2019, 46, 91-97.	1.7	4

#	Article	IF	CITATIONS
37	Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women. Contraception, 2018, 97, 357-362.	1.5	15
38	Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. Journal of the International AIDS Society, 2018, 21, e25081.	3.0	58
39	The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa. Lancet Infectious Diseases, The, 2018, 18, e288-e294.	9.1	68
40	Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?. Retrovirology, 2018, 15, 29.	2.0	46
41	Advancing STI priorities in the SDG era: priorities for action. Globalization and Health, 2018, 14, 6.	4.9	6
42	Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 566-572.	2.1	24
43	Longitudinal patterns of unmet need for contraception among women living with HIV on antiretroviral therapy in South Africa. PLoS ONE, 2018, 13, e0209114.	2.5	13
44	Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Globalization and Health, 2018, 14, 102.	4.9	46
45	Collateral benefits: how the practical application of Good Participatory Practice can strengthen <scp>HIV</scp> research in subâ€Saharan Africa. Journal of the International AIDS Society, 2018, 21, e25175.	3.0	10
46	Special focus on challenges and opportunities for the development and use of vaccines in Africa. Human Vaccines and Immunotherapeutics, 2018, 14, 2335-2339.	3.3	19
47	Impacts of Climate Change on Health and Wellbeing in South Africa. International Journal of Environmental Research and Public Health, 2018, 15, 1884.	2.6	69
48	Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2018, 18, 1241-1250.	9.1	68
49	Designing PrEP and early HIV treatment interventions for implementation among female sex workers in South Africa: developing and learning from a formative research process. BMJ Open, 2018, 8, e019292.	1.9	12
50	Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine, 2018, 36, 4830-4836.	3.8	27
51	Safety of a silicone elastomer vaginal ring as potential microbicide delivery method in African women: A Phase 1 randomized trial. PLoS ONE, 2018, 13, e0196904.	2.5	5
52	How climate change can fuel listeriosis outbreaks in South Africa. South African Medical Journal, 2018, 108, 453.	0.6	12
53	Human Papillomavirus Vaccine Introduction in South Africa: Implementation Lessons From an Evaluation of the National School-Based Vaccination Campaign. Global Health, Science and Practice, 2018, 6, 425-438.	1.7	48
54	"lt Was Not My Aim to Sleep Thereâ€. The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis. AIDS and Behavior, 2018, 22, 3692-3704.	2.7	7

#	Article	lF	CITATIONS
55	Estimating the Population Size of Female Sex Workers in Three South African Cities: Results and Recommendations From the 2013-2014 South Africa Health Monitoring Survey and Stakeholder Consensus. JMIR Public Health and Surveillance, 2018, 4, e10188.	2.6	10
56	HIV retesting in pregnant women in South Africa: Outcomes of a quality improvement project targeting health systems' weaknesses. Southern African Journal of HIV Medicine, 2018, 19, 784.	0.9	3
57	Guidelines to support HIV-affected individuals and couples to achieve pregnancy safely: Update 2018. Southern African Journal of HIV Medicine, 2018, 19, 915.	0.9	25
58	When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study. Journal of the International AIDS Society, 2017, 20, 21744.	3.0	18
59	User perspectives on Implanon NXT in South Africa: A survey of 12 public-sector facilities. South African Medical Journal, 2017, 107, 815.	0.6	34
60	At the Heart of the Problem: Health in Johannesburg's Inner-City. BMC Public Health, 2017, 17, 554.	2.9	12
61	Sexual and reproductive health outcomes among female sex workers in Johannesburg and Pretoria, South Africa: Recommendations for public health programmes. BMC Public Health, 2017, 17, 442.	2.9	22
62	Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa. BMC Public Health, 2017, 17, 524.	2.9	1
63	Pre-exposure rabies prophylaxis: a systematic review. Bulletin of the World Health Organization, 2017, 95, 210-219C.	3.3	89
64	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 1534-1540.	4.0	18
65	Strengthening implant provision and acceptance in South Africa with the †Any woman, any place, any time†approach: An essential step towards reducing unintended pregnancies. South African Medical Journal, 2017, 107, 939.	0.6	16
66	Gaps in monitoring systems for Implanon NXT services in South Africa: An assessment of 12 facilities in two districts. South African Medical Journal, 2017, 107, 827.	0.6	11
67	Lessons learnt from the introduction of the contraceptive implant in South Africa. South African Medical Journal, 2017, 107, 933.	0.6	31
68	Contraception coverage and methods used among women in South Africa: A national household survey. South African Medical Journal, 2017, 107, 307.	0.6	73
69	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq1	. 017184314	1 rg&T /Overl
70	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq0 (	) 01r. <b>g</b> BT /C	verbock 10 T
71	HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. PLoS Medicine, 2017, 14, e1002444.	8.4	124
72	Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clinical Infectious Diseases, 2016, 62, civ908.	5.8	21

#	Article	IF	CITATIONS
73	Growing inequities in maternal health in South Africa: a comparison of serial national household surveys. BMC Pregnancy and Childbirth, 2016, 16, 256.	2.4	26
74	Low Receipt and Uptake of Safer Conception Messages in Routine HIV Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 105-113.	2.1	22
75	Establishing conception intentions and safer conception services for eliminating the vertical, and reducing the horizontal, transmission of <scp>HIV</scp> . BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1585-1588.	2.3	8
76	Planning for HIV preexposure prophylaxis introduction. Current Opinion in HIV and AIDS, 2016, 11, 87-93.	3.8	47
77	Field evaluation of Standard Diagnostics' Bioline HIV/Syphilis Duo test among female sex workers in Johannesburg, South Africa. Sexually Transmitted Infections, 2016, 92, 495-498.	1.9	30
78	<i>Treatment <i>A</i> nd <i>P</i> revention for female <i>S</i> ex workers in South Africa: protocol for the TAPS Demonstration Project. BMJ Open, 2016, 6, e011595.	1.9	15
79	The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. Vaccine, 2016, 34, 2939-2947.	3.8	109
80	The Cape Town Declaration on Vaccines 2012: Unlocking the full potential of vaccines in Africa. Vaccine, 2016, 34, 3713-3714.	3.8	1
81	Local and foreign authorship of maternal health interventional research in low- and middle-income countries: systematic mapping of publications 2000–2012. Globalization and Health, 2016, 12, 35.	4.9	47
82	Mapping of research on maternal health interventions in low- and middle-income countries: a review of 2292 publications between 2000 and 2012. Globalization and Health, 2016, 12, 52.	4.9	17
83	Perspectives on the methods of a large systematic mapping of maternal health interventions. Globalization and Health, 2016, 12, 51.	4.9	3
84	Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. Journal of Infectious Diseases, 2016, 213, 551-555.	4.0	17
85	"Bitten By Shyness― Menstrual Hygiene Management, Sanitation, and the Quest for Privacy in South Africa. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2016, 35, 161-176.	1.2	47
86	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)–Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2–Coinfected Individuals. Journal of Infectious Diseases, 2016, 213, 1573-1578.	4.0	10
87	Increased Access to Antiretroviral Therapy Is Associated with Reduced Maternal Mortality in Johannesburg, South Africa: An Audit from 2003-2012. PLoS ONE, 2016, 11, e0168199.	2.5	6
88	Mass vaccination of dogs, control of canine populations and postâ€exposure vaccination – necessary but not sufficient for achieving childhood rabies elimination. Tropical Medicine and International Health, 2015, 20, 682-684.	2.3	6
89	Contraceptive implants and efavirenz-based ART: friend or foe?. Lancet HIV,the, 2015, 2, e454-e455.	4.7	3
90	Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. Aids, 2015, 29, 2353-2359.	2.2	43

#	Article	IF	CITATIONS
91	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. PLoS Medicine, 2015, 12, e1001778.	8.4	170
92	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1–Serodiscordant Couples. Journal of Infectious Diseases, 2015, 211, 1451-1460.	4.0	47
93	Path to impact: A report from the Bill and Melinda Gates Foundation convening on maternal immunization in resource-limited settings; Berlin – January 29–30, 2015. Vaccine, 2015, 33, 6388-6395.	3.8	24
94	HIV prevalence and risk in long-distance truck drivers in South Africa: a national cross-sectional survey. International Journal of STD and AIDS, 2014, 25, 428-438.	1.1	69
95	Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Human Reproduction, 2014, 29, 1810-1817.	0.9	29
96	Preparing for PrEP & Demonstration Project in South Africa. AIDS Research and Human Retroviruses, 2014, 30, A269-A270.	1.1	4
97	Motivating, Measuring and Monitoring Adherence in the FACTS 001 Tenofovir Gel Microbicide Study. AIDS Research and Human Retroviruses, 2014, 30, A169-A169.	1.1	3
98	Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet, The, 2014, 384, 272-279.	13.7	107
99	HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine, 2014, 32, 1595-1601.	3.8	102
100	Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infectious Diseases, 2014, 14, 14.	2.9	28
101	Hidden harms: Women's narratives of intimate partner violence in a microbicide trial, South Africa. Social Science and Medicine, 2014, 110, 49-55.	3.8	36
102	Rabies: Underused vaccines, unnecessary deaths. Vaccine, 2014, 32, 2017-2019.	3.8	16
103	WhatsApp!: Use of Mobile Technology in Optimizing ASPIRE Study Retention and Adherence at the Wits Reproductive Health and HIV Institute, Johannesburg. AIDS Research and Human Retroviruses, 2014, 30, A28-A28.	1.1	0
104	Pre-screening Strategies to Enhance Accrual and Retention in the ASPIRE Trial at the Wits Reproductive Health and HIV Institute, Johannesburg. AIDS Research and Human Retroviruses, 2014, 30, A80-A80.	1.1	0
105	Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation. Clinical Infectious Diseases, 2014, 59, S21-S27.	5.8	86
106	Vaccines against sexually transmitted infections: The way forward. Vaccine, 2014, 32, 1630-1637.	3.8	37
107	The STI vaccine roadmapâ€"A long overdue intervention. Vaccine, 2014, 32, 1638-1639.	3.8	2
108	A Prospective Study of the Effect of Pregnancy on CD4 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1–Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 231-236.	2.1	27

#	Article	IF	CITATIONS
109	Using HPV vaccination for promotion of an adolescent package of care: opportunity and perspectives. BMC Public Health, 2013, 13, 493.	2.9	20
110	Hormonal contraceptive use and risk of HIV-1 disease progression. Aids, 2013, 27, 261-267.	2.2	33
111	Short-Course Antiretroviral Therapy in Primary HIV Infection. New England Journal of Medicine, 2013, 368, 207-217.	27.0	194
112	Intersection of HIV and Reproductive Health. AIDS Research and Treatment, 2013, 2013, 1-2.	0.7	0
113	Ethical considerations for vaccination programmes in acute humanitarian emergencies. Bulletin of the World Health Organization, 2013, 91, 290-297.	3.3	38
114	Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial. Journal of Infectious Diseases, 2013, 208, 1366-1374.	4.0	45
115	Controlling the HIV Epidemic with Antiretrovirals. Journal of the International Association of Providers of AIDS Care, 2013, 12, 208-216.	1.5	36
116	Pre-exposure prophylaxis for HIV prevention: Ready for prime time in South Africa?. South African Medical Journal, 2013, 103, 515.	0.6	13
117	How Much Demand for New HIV Prevention Technologies Can We Really Expect? Results from a Discrete Choice Experiment in South Africa. PLoS ONE, 2013, 8, e83193.	2.5	53
118	Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-7.	1.5	5
119	Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. Aids, 2012, 26, 513-518.	2.2	35
120	Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases, The, 2012, 12, 19-26.	9.1	375
121	Use of hormonal contraceptives and risk of HIV-1 transmission – Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 510-511.	9.1	17
122	High Incidence of Unplanned Pregnancy after Antiretroviral Therapy Initiation: Findings from a Prospective Cohort Study in South Africa. PLoS ONE, 2012, 7, e36039.	2.5	123
123	High Pregnancy Intentions and Missed Opportunities for Patient–Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy. AIDS and Behavior, 2012, 16, 69-78.	2.7	86
124	A Tale of Two Countries: Rethinking Sexual Risk for HIV Among Young People in South Africa and the United States. Journal of Adolescent Health, 2011, 49, 237-243.e1.	2.5	36
125	Will the Decade of Vaccines mean business as usual?. Lancet, The, 2011, 378, 382-385.	13.7	7
126	Antiretrovirals for safer conception for HIV-negative women and their HIV-1-infected male partners. Aids, 2011, 25, 2049-2051.	2.2	4

#	Article	IF	Citations
127	Increased risk of HIV-1 transmission in pregnancy. Aids, 2011, 25, 1887-1895.	2.2	219
128	Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. Journal of the International AIDS Society, 2011, 14, 42-42.	3.0	65
129	Continued High Risk Sexual Behavior Following Diagnosis with Acute HIV Infection in South Africa and Malawi: Implications for Prevention. AIDS and Behavior, 2011, 15, 1243-1250.	2.7	54
130	Investing in the future: lessons learnt from communicating the results of HSV/ HIV intervention trials in South Africa. Health Research Policy and Systems, 2011, 9, S8.	2.8	18
131	Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. PLoS Medicine, 2011, 8, e1001123.	8.4	130
132	Concurrent Sexual Partnerships and Human Immunodeficiency Virus Risk Among South African Youth. Sexually Transmitted Diseases, 2011, 38, 459-466.	1.7	64
133	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. PLoS ONE, 2010, 5, e12598.	2.5	129
134	Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine, 2010, 362, 427-439.	27.0	476
135	Causal links between binge drinking patterns, unsafe sex and HIV in South Africa: its time to intervene. International Journal of STD and AIDS, 2010, 21, 2-7.	1.1	59
136	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet, The, 2010, 375, 824-833.	13.7	142
137	PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet, The, 2010, 376, 1329-1337.	13.7	311
138	Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study. PLoS ONE, 2009, 4, e5272.	2.5	71
139	Managing men: women's dilemmas about overt and covert use of barrier methods for HIV prevention. Culture, Health and Sexuality, 2009, 11, 485-497.	1.8	42
140	Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. Aids, 2009, 23, 1531-1538.	2.2	77
141	Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. Aids, 2009, 23, 461-469.	2.2	91
142	Factors associated with HIV testing among sexually active South African youth aged 15–24 years. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 456-467.	1.2	106
143	Bone mineral density in young women aged $19\hat{a}\in 24$ after $4\hat{a}\in 5$ years of exclusive and mixed use of hormonal contraception. Contraception, 2009, 80, 128-132.	1.5	24
144	Use of injectable progestin contraception and risk of STI among South African women. Contraception, 2009, 80, 555-560.	1.5	33

#	Article	IF	Citations
145	Sexual Violence and Reproductive Health Outcomes Among South African Female Youths: A Contextual Analysis. American Journal of Public Health, 2009, 99, S425-S431.	2.7	27
146	Early Coital Debut and Associated HIV Risk Factors Among Young Women and Men in South Africa. International Perspectives on Sexual and Reproductive Health, 2009, 35, 82-90.	3.7	83
147	Consistent Condom Use in South African Youth's Most Recent Sexual Relationships. AIDS and Behavior, 2008, 12, 431-440.	2.7	44
148	Orphanhood and Completion of Compulsory School Education Among Young People in South Africa: Findings From a National Representative Survey. Journal of Research on Adolescence, 2008, 18, 173-186.	3.7	33
149	Keep them in school: the importance of education as a protective factor against HIV infection among young South African women. International Journal of Epidemiology, 2008, 37, 1266-1273.	1.9	133
150	"You Must Do the Test to Know Your Status†Attitudes to HIV Voluntary Counseling and Testing for Adolescents Among South African Youth and Parents. Health Education and Behavior, 2008, 35, 87-104.	2.5	83
151	Safety and Efficacy of Initiating Highly Active Antiretroviral Therapy in an Integrated Antenatal and HIV Clinic in Johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 276-281.	2.1	44
152	Introduction: Addressing the vulnerability of young women and girls to stop the HIV epidemic in southern Africa. Aids, 2008, 22, S1-S3.	2.2	26
153	HIV and Sexual Behavior Among Young People: The South African Paradox. Sexually Transmitted Diseases, 2008, 35, 843-844.	1.7	24
154	Male circumcision is an efficacious, lasting and cost-effective strategy for combating HIV in high-prevalence AIDS epidemics. Future HIV Therapy, 2008, 2, 399-405.	0.4	34
155	Vulnerability of women in southern Africa to infection with HIV: biological determinants and priority health sector interventions. Aids, 2008, 22, S27-S40.	2.2	94
156	Vaginal practices, microbicides and HIV: what do we need to know?. Sexually Transmitted Infections, 2007, 83, 505-508.	1.9	56
157	Challenge of evaluating a national HIV prevention programme: the case of loveLife, South Africa. Sexually Transmitted Infections, 2007, 83, i70-i74.	1.9	38
158	Prevalence of Parental Death Among Young People in South Africa and Risk for HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 93-98.	2.1	65
159	Predictors of Condom Use Among Young Adults in South Africa: The Reproductive Health and HIV Research Unit National Youth Survey. American Journal of Public Health, 2007, 97, 1241-1248.	2.7	157
160	Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on ‬Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January–2 February 2006, IAVI, New York, USA. Aids, 2007, 21, 539-546.	2.2	10
161	Highly efficient HIV transmission to young women in South Africa. Aids, 2007, 21, 861-865.	2.2	42
162	Predictors of dual method use for pregnancy and HIV prevention among adolescent South African women. Contraception, 2007, 75, 383-389.	1.5	38

#	Article	IF	Citations
163	Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception, 2007, 75, 461-467.	1.5	75
164	Contraception use and pregnancy among $15\hat{a}\in$ "24 year old South African women: a nationally representative cross-sectional survey. BMC Medicine, 2007, 5, 31.	5.5	67
165	Geographic distribution of human immunodeficiency virus in South Africa. American Journal of Tropical Medicine and Hygiene, 2007, 77, 1163-9.	1.4	31
166	Factors Associated With Self-Efficacy for Condom Use and Sexual Negotiation Among South African Youth. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 226-233.	2.1	118
167	The Importance of Context: Model Projections on How Microbicide Impact Could Be Affected by the Underlying Epidemiologic and Behavioral Situation in 2 African Settings. Sexually Transmitted Diseases, 2006, 33, 397-405.	1.7	33
168	Response to letters from Jewkes, Parker and Colvin, and Potterat et al Aids, 2006, 20, 956-958.	2.2	1
169	Are Targeted HIV Prevention Activities Cost-Effective in High Prevalence Settings? Results From a Sexually Transmitted Infection Treatment Project for Sex Workers in Johannesburg, South Africa. Sexually Transmitted Diseases, 2006, 33, S122-S132.	1.7	47
170	Heterosexual anal intercourse increases risk of HIV infection among young South African men. Aids, 2006, 20, 123-125.	2.2	80
171	Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. Aids, 2005, 19, 1525-1534.	2.2	473
172	The impact of age on the epidemiology of incomplete abortions in South Africa after legislative change. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 355-359.	2.3	67
173	Why are women still aborting outside designated facilities in metropolitan South Africa?. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1236-1242.	2.3	89
174	A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: results of the baseline survey. Tropical Medicine and International Health, 2005, 10, 971-980.	2.3	76
175	Risk factors for HIV infection among sex workers in Johannesburg, South Africa. International Journal of STD and AIDS, 2005, 16, 256-261.	1.1	46
176	Sexual Power and HIV Risk, South Africa1. Emerging Infectious Diseases, 2004, 10, 1996-2004.	4.3	270
177	Abortion Service Provision in South Africa Three Years After Liberalization of the Law. Studies in Family Planning, 2003, 34, 277-284.	1.8	27
178	Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate. Contraception, 2003, 68, 339-343.	1.5	9
179	Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. Aids, 2003, 17, 321-329.	2.2	83
180	Dual protection in sexually active women. South African Medical Journal, 2003, 93, 854-7.	0.6	14

#	Article	IF	Citations
181	Prevalence of morbidity associated with abortion before and after legalisation in South Africa. BMJ: British Medical Journal, 2002, 324, 1252-1253.	2.3	51
182	A Case Study of Antenatal Syphilis Screening in South Africa. Sexually Transmitted Diseases, 2002, 29, 32-37.	1.7	15
183	Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet, The, 2002, 360, 971-977.	13.7	755
184	Structural integrity of the female condom after multiple uses, washing, drying, and re-lubrication. Contraception, 2001, 63, 33-36.	1.5	23
185	Temporary discontinuation: a compliance issue in injectable users. Contraception, 2001, 64, 309-313.	1.5	15
186	The Acceptability of Reuse of the Female Condom Among Urban South African Women. Journal of Urban Health, 2001, 78, 647-657.	3.6	15
187	Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. Aids, 2000, 14, 85-88.	2.2	91
188	In vitro assessment of the structural integrity of the female condom after multiple wash, dry, and re-lubrication cycles. Contraception, 2000, 61, 271-276.	1.5	13
189	High Knowledge and High Risk Behaviour: A Profile of Hotel-Based Sex Workers in Inner-City Johannesburg. African Journal of Reproductive Health, 2000, 4, 35.	1.1	19
190	The practice and prevalence of dry sex among men and women in South Africa: a risk factor for sexually transmitted infections?. Sexually Transmitted Infections, 1999, 75, 178-180.	1.9	54
191	Severe acute maternal morbidity: a pilot study of a definition for a near-miss. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 985-990.	2.3	318
192	Methodological Issues in the South African Incomplete Abortion Study. Studies in Family Planning, 1997, 28, 228.	1.8	16
193	Acquiring the pill: Safety issues. Reproductive Health Matters, 1994, 2, 41-45.	1.2	0
194	Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. SSRN Electronic Journal, 0, , .	0.4	0